IMMUPHARMA PLC — Director's Dealing 2015

Nov 30, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3784H

Immupharma PLC

30 November 2015

FOR IMMEDIATE RELEASE                                                                30 NOVEMBER 2015

TR-1 NOTIFICATION OF MAJOR INTEREST IN SHARES BY AVIVA

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, confirms that it has received a TR-1 by Aviva plc, providing an update on its direct and indirect share allocation via its subsidiaries. The total holding remains the same at 8,140,848 Ordinary Shares or 9.19% of the issued share capital. Aviva is one of the largest institutional shareholders in ImmuPharma.

The full TR-1 disclosure can be seen below.

For further information please contact:

ImmuPharma plc	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD & Broker	+44 (0) 20 7886 2500
Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking

TR-1 : MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			Immupharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	NOTIFICATION PROMPTED BY THE REMOVAL OF STOCK LENDING EXEMPTION FOLLOWING IMPLEMENTATION OF THE EU TRANSPARENCY DIRECTIVE AMENDMENTS			x
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s) (if different from 3.):iv		Registered Holder: BNY Norwich Union Nominees Limited         232,080*                                                               Chase (GA Group) Nominees Limited          6,809,654* *denotes direct interest   Chase (GA Group) Nominees Limited             373,991 Chase Nominees Limited                        150,841 Vidacos Nominees Limited                                 406,282
5. Date of the transaction and date on which the threshold is crossed or reached: v		25 November 2015
6. Date on which issuer notified:		27 November 2015
7. Threshold(s) that is/are crossed or reached: vi, vii		8% to 7% Change at Direct Interest Level

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights		% of  voting rights x
Direct	Direct xi	Indirect xii	Direct		Indirect
Ordinary Shares GB0033711010	8,143,876		8,143,876		7,972,848	7,041,734	931,114	7.95%		1.05%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv		Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
RIGHT TO RECALL LOANED SHARES	N/A	N/A	N/A	168,000 *  * Direct interest	Nominal	Delta
0.19%

Total (A+B+C)
Number of voting rights	Percentage of voting rights
8,140,848	9.19%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based the total number of voting rights of  88,622,463 as per the recent Additional Listing - Conditional Placing announcement of 21 October 2014.
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	01603 684420

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLFBLFXEFFEFBZ